. 2021 May 1;110(2):432–442. doi: 10.1002/cpt.2227

Table 1.

Predicted K_p,uu,brain using method 1, i.e., from in vitro ER

Compound	Exp.	ER_TRQ(‐)	ER_TRQ(+)	ER_TRQ(‐) ‐ ER_TRQ(+)	REF	K_{p,uu,brain,pred(method 1)}		K_{p,uu,brain,obs} (CI_95%)	P/O
Compound	Exp.	ER_TRQ(‐)	ER_TRQ(+)	ER_TRQ(‐) ‐ ER_TRQ(+)	REF	Individual	Mean ± SD	K_{p,uu,brain,obs} (CI_95%)	P/O
Verapamil	1	2.94	0.76	2.18	2.20	0.17	0.17 ± 0.03	0.16 (0.13–0.20)	1.02
	2	2.97	0.76	2.21	2.39	0.16
	3	3.59	0.71	2.88	2.37	0.13
	4	3.73	0.83	2.90	1.32	0.21
N‐desmethyl loperamide	1	18.28	0.86	17.42	0.97	0.056	0.043 ± 0.018	0.046 (0.035–0.057)	0.92
	2	26.21	0.82	25.39	1.83	0.021
	3	55.00	0.98	54.02	0.30	0.058
	4	119.43	0.82	118.61	0.23	0.035
Metoclopramide	1	1.87	0.70	1.17	0.30	0.74	0.74 ± 0.08	0.57 (0.46–0.67)	1.30
	2	1.79	0.92	0.87	0.36	0.76
	3	3.56	1.03	2.53	0.24	0.63
	4	2.98	1.68	1.30	0.18	0.81

CI_95%, 95% confidence interval; ER, efflux ratio; Exp., experiment; K_p,uu,brain, unbound brain‐to‐plasma concentration ratio; P/O, predicted/observed K_p,uu,brain ratio; REF, relative expression factor (measured by targeted proteomics); TRQ, tariquidar.